1961 related articles for article (PubMed ID: 17704786)
1. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Obeid M; Ortiz C; Criollo A; Mignot G; Maiuri MC; Ullrich E; Saulnier P; Yang H; Amigorena S; Ryffel B; Barrat FJ; Saftig P; Levi F; Lidereau R; Nogues C; Mira JP; Chompret A; Joulin V; Clavel-Chapelon F; Bourhis J; André F; Delaloge S; Tursz T; Kroemer G; Zitvogel L
Nat Med; 2007 Sep; 13(9):1050-9. PubMed ID: 17704786
[TBL] [Abstract][Full Text] [Related]
2. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
4. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
5. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
6. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
7. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant role for cell death during chemo- and radiotherapy of cancer?
Rovere-Querini P; Castiglioni A
Expert Rev Clin Immunol; 2008 Jan; 4(1):27-32. PubMed ID: 20477584
[TBL] [Abstract][Full Text] [Related]
9. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
[TBL] [Abstract][Full Text] [Related]
11. The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway.
Uto T; Akagi T; Yoshinaga K; Toyama M; Akashi M; Baba M
Biomaterials; 2011 Aug; 32(22):5206-12. PubMed ID: 21492934
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
14. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule.
Lysakova-Devine T; Keogh B; Harrington B; Nagpal K; Halle A; Golenbock DT; Monie T; Bowie AG
J Immunol; 2010 Oct; 185(7):4261-71. PubMed ID: 20802145
[TBL] [Abstract][Full Text] [Related]
15. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
16. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
[TBL] [Abstract][Full Text] [Related]
17. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response.
Núñez NG; Andreani V; Crespo MI; Nocera DA; Breser ML; Morón G; Dejager L; Libert C; Rivero V; Maccioni M
Cancer Res; 2012 Feb; 72(3):592-603. PubMed ID: 22139376
[TBL] [Abstract][Full Text] [Related]
18. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo.
Andreani V; Gatti G; Simonella L; Rivero V; Maccioni M
Cancer Res; 2007 Nov; 67(21):10519-27. PubMed ID: 17974996
[TBL] [Abstract][Full Text] [Related]
19. Requirement of the acquired immune system in successful cancer chemotherapy with cis-diamminedichloroplatinum (II) in a syngeneic mouse tumor transplantation model.
Taniguchi K; Nishiura H; Yamamoto T
J Immunother; 2011; 34(6):480-9. PubMed ID: 21654518
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
